


5124: Outcome of adult B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab in addition to chemotherapy independent of MRD: First results from the national GMALL registry

Nicola Göbke, Matthias Stelljes, Walter Fiedler, Jens Panse, Andreas Viardot, Lisa Heberling, Wolfram Jung, Christoph Faul, Maher Hanoun, Kathrin Nachtkamp, Jürgen Krauter, Heidrun Hindahl, Andrea Renzelmann, Veit Buecklein, Stefan Schwartz, Lena Reiser, Monika Brüggemann, Thomas Oellerich, Hubert Serve, Björn Steffen

Universitätsklinikum Frankfurt Med. Klinik II & GMALL; Universitätsklinikum Münster, Med. Klinik A; Universitätsklinikum Hamburg-Eppendorf, II. Medizinische Klinik; Uniklinik RWTH Aachen, Med. Klinik IV; Universitätsklinikum Ulm, Innere Medizin III; Universitätsklinikum Leipzig, Hämatologie & Zelltherapie; Gemeinschaftspraxis Hämatologie/Onkologie Köln; Universitätsklinikum Tübingen, Med. Klinik II; Universitätsklinikum Essen, Klinik für Hämatologie; Universitätsklinikum Düsseldorf, Klinik für Hämatologie/Onkologie; Klinikum Braunschweig, Med. Klinik III; Klinikum Braunschweig, Med. Klinik III; Klinikum Oldenburg, Onkologie & Hämatologie; LMU Klinikum München, Medizinische Klinik III; Charité Berlin, Med. Klinik m.S. Hämatologie/Onkologie; Universitätsklinikum Frankfurt, Med. Klinik II; UKSH Kiel, Hämatologische Spezialdiagnostik; Universitätsklinikum Frankfurt, Med. Klinik II; Universitätsklinikum Frankfurt, Med. Klinik II; Universitätsklinikum Frankfurt, Med. Klinik II.

SCHEDULE



COHORTS

Cohort 1 (modified)	Cohort 2 (standard)
8/23–8/24	8/16–8/23
Registry 18–75 yrs	GMALL08 for 18–55 yrs Registry 18–75 yrs
14 (0.2–22) mo	46 (0.4–104) mo

BLINA REALIZATION IN COHORT 1

Younger	76%
Older	65%

The GMALL Trial 08/2013 is an independent academic trial of the Goethe University was funded by Deutsche Krebshilfe (111440)

Reference: Blood (2025) 146 (Supplement 1): 5124.
<https://doi.org/10.1182/blood-2025-5124>

PATIENTS

	Cohort 1	Cohort 2
Total	199	1036
Age		
Young (18–55y)	131 (66%)	737 (71%)
Old (>55y)	68 (34%)	299 (29%)
Risk Group		
HR	77 (39%)	449 (44%)
SR	122 (61%)	582 (56%)
Subtype		
c/pre B	170 (85%)	800 (81%)
Pro B	29 (15%)	189 (19%)

SURVIVAL 18 Mo COHORT 2 vs 1

TOTAL			
Younger	83%	→	91%
Older	64%	→	74%
CR Pts			
Younger	90%	→	95%
Older	77%	→	87%
MolIMR			
Younger	73%	→	94%
Older	79%	→	94%

OVERALL SURVIVAL 18-55y Mo 18

GMALL08/2013	89%
Cohort 2/no trial	75%
Cohort 1/no trial	85%

Summary

- Addition of upfront Blina improves outcome in all subgroups
- Best outcome in GMALL 08 (w/o upfront Blina)
- In-trial therapy is superior !

CONTACT

Web: gmallstudien.de
Mail: gmall@em.uni-frankfurt.de